-
1 Comment
Alphamab Oncology is currently in a long term uptrend where the price is trading 55.4% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Its net income has increased by 58.1% to $-325M since the same quarter in the previous year.
Finally, its free cash flow grew by 48.1% to $-119M since the same quarter in the previous year.
Based on the above factors, Alphamab Oncology gets an overall score of 4/5.
| CurrencyCode | HKD |
|---|---|
| ISIN | KYG0330A1013 |
| Exchange | HK |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 6B |
|---|---|
| PE Ratio | 36.11 |
| Target Price | 4.818 |
| Beta | 0.41 |
| Dividend Yield | None |
Alphamab Oncology, a clinical stage biopharmaceutical company, engages in the research, development, manufacture, and commercialization of oncology biologics. The company commercializes KN035, an injectable PD-L1 inhibitor for the treatment of adult patients with unresectable or metastatic microsatellite instability-high/efficient mismatch repair advanced solid tumors under the ENQEIDA brand name. Its product pipeline includes KN026, a next generation anti-human epidermal growth factor receptor 2 (HER2) bispecific monoclonal antiboday that is in Phase III clinical trials for treatment of HER2-positive breast cancer and HER2- positive gastric cancer or gastroesophageal junction cancer; JSKN003, a biparatopic HER2-targeting antibody-drug conjugate that is in Phase I/II clinical trial for the treatment of HER2-expressing advanced or metastatic solid tumors; JSKN016, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced malignant solid tumors; and JSKN033, a subcutaneous antibody-drug conjugate to treat HER2-expressing advanced or metastatic solid tumors. Alphamab Oncology was founded in 2008 and is headquartered in Suzhou, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 9966.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
